10-Q Filing

MERCK & CO., INC. CIK: 310158 Q1 2024

Filing Information

Form Type	10-Q
Accession Number	`0001628280-24-020283`
Period End Date	20240331
Filing Date	20240503
Fiscal Year	2024
Fiscal Period	Q1
XBRL Instance	mrk-20240331_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 156 Income Statement 56 Cash Flow Statement 128 Comprehensive Income 24

Balance Sheet 156 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$88.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$88.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$80.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$80.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$3.41B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$3.41B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$3.35B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$3.35B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.62B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.62B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.84B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.84B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.58B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$5.58B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.27B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.27B	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$40.00M	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$40.00M	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$252.00M	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$252.00M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $80 in 2024 and $88 in 2023)	`AccountsReceivableNetCurrent`	$10.35B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $80 in 2024 and $88 in 2023)	`AccountsReceivableNetCurrent`	$10.35B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $80 in 2024 and $88 in 2023)	`AccountsReceivableNetCurrent`	$11.37B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $80 in 2024 and $88 in 2023)	`AccountsReceivableNetCurrent`	$11.37B	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6)	`InventoryNet`	$6.51B	USD	Point-in-time
Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6)	`InventoryNet`	$6.51B	USD	Point-in-time
Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6)	`InventoryNet`	$6.36B	USD	Point-in-time
Inventories (excludes inventories of $3,413 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6)	`InventoryNet`	$6.36B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$7.95B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$7.95B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$8.37B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$8.37B	USD	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.05B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.05B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.04B	shares	Point-in-time
Total current assets	`AssetsCurrent`	$32.17B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$32.17B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$31.45B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$31.45B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$280.00M	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$280.00M	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$252.00M	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$252.00M	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620 in 2024 and $18,266 in 2023	`PropertyPlantAndEquipmentNet`	$23.05B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620 in 2024 and $18,266 in 2023	`PropertyPlantAndEquipmentNet`	$23.05B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620 in 2024 and $18,266 in 2023	`PropertyPlantAndEquipmentNet`	$23.05B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,620 in 2024 and $18,266 in 2023	`PropertyPlantAndEquipmentNet`	$23.05B	USD	Point-in-time
Goodwill	`Goodwill`	$21.18B	USD	Point-in-time
Goodwill	`Goodwill`	$21.18B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$17.57B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$17.57B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$18.01B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$18.01B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$12.00B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$12.00B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$12.33B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$12.33B	USD	Point-in-time
Total Assets	`Assets`	$105.85B	USD	Point-in-time
Total Assets	`Assets`	$105.85B	USD	Point-in-time
Total Assets	`Assets`	$106.67B	USD	Point-in-time
Total Assets	`Assets`	$106.67B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$3.08B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$3.08B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$1.37B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$1.37B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.92B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.92B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.51B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.51B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$15.77B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$15.77B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$14.10B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$14.10B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$2.65B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$2.65B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$2.40B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$2.40B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.99B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.99B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$2.01B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$2.01B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.69B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.69B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.10B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.10B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$33.68B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$33.68B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$31.14B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$31.14B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$922.00M	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$922.00M	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$871.00M	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$871.00M	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.79B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.79B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.26B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.26B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.60B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.60B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.51B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.51B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$56.70B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$56.70B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$53.90B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$53.90B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.16B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.16B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.27B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.27B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$95.03B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$95.03B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$97.81B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$97.81B	USD	Point-in-time
Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023	`TreasuryStockCommonValue`	$57.45B	USD	Point-in-time
Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023	`TreasuryStockCommonValue`	$57.45B	USD	Point-in-time
Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023	`TreasuryStockCommonValue`	$57.45B	USD	Point-in-time
Less treasury stock, at cost: 1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023	`TreasuryStockCommonValue`	$57.45B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$37.58B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$37.58B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$40.36B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$40.36B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$60.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$60.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$54.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$54.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.91B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.91B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$40.42B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$40.42B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$37.63B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$37.63B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$105.85B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$105.85B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$106.67B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$106.67B	USD	Point-in-time

Income Statement 56 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$15.78B	USD	1 Quarter
Sales	`Revenues`	$15.78B	USD	1 Quarter
Sales	`Revenues`	$14.49B	USD	1 Quarter
Sales	`Revenues`	$14.49B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$3.93B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$3.93B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$3.54B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$3.54B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.48B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.48B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.48B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.48B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$4.28B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$4.28B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.99B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.99B	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$123.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$123.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$67.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$67.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-89.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-89.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$33.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$33.00M	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.11B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.11B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.84B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.84B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$5.67B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$5.67B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$3.65B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$3.65B	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$825.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$825.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$903.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$903.00M	USD	1 Quarter
Net Income	`ProfitLoss`	$2.83B	USD	1 Quarter
Net Income	`ProfitLoss`	$2.83B	USD	1 Quarter
Net Income	`ProfitLoss`	$4.77B	USD	1 Quarter
Net Income	`ProfitLoss`	$4.77B	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$5.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$5.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$4.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$4.00M	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.82B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.82B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.76B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.76B	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.11	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.11	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.88	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.88	USD	1 Quarter
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.87	USD	1 Quarter
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.87	USD	1 Quarter
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.11	USD	1 Quarter
Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.11	USD	1 Quarter

Cash Flow Statement 128 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$68.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$68.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$92.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$92.00M	USD	Point-in-time
Net income	`ProfitLoss`	$2.83B	USD	1 Quarter
Net income	`ProfitLoss`	$2.83B	USD	1 Quarter
Net income	`ProfitLoss`	$4.77B	USD	1 Quarter
Net income	`ProfitLoss`	$4.77B	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$473.00M	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$473.00M	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$543.00M	USD	1 Quarter
Amortization	`AdjustmentForAmortization`	$543.00M	USD	1 Quarter
Depreciation	`Depreciation`	$448.00M	USD	1 Quarter
Depreciation	`Depreciation`	$448.00M	USD	1 Quarter
Depreciation	`Depreciation`	$511.00M	USD	1 Quarter
Depreciation	`Depreciation`	$511.00M	USD	1 Quarter
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$143.00M	USD	1 Quarter
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$143.00M	USD	1 Quarter
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$450.00M	USD	1 Quarter
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$450.00M	USD	1 Quarter
Charge for the acquisition of Harpoon Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo`	$656.00M	USD	1 Quarter
Charge for the acquisition of Harpoon Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo`	$656.00M	USD	1 Quarter
Charge for the acquisition of Harpoon Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo`	-	USD	1 Quarter
Charge for the acquisition of Harpoon Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffAssetAcquisitionTwo`	-	USD	1 Quarter
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	1 Quarter
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	1 Quarter
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$1.19B	USD	1 Quarter
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$1.19B	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-51.00M	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-51.00M	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-277.00M	USD	1 Quarter
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-277.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$145.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$145.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$176.00M	USD	1 Quarter
Share-based compensation	`ShareBasedCompensation`	$176.00M	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$-83.00M	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$-83.00M	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$197.00M	USD	1 Quarter
Other	`OtherNoncashIncomeExpense`	$197.00M	USD	1 Quarter
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.89B	USD	1 Quarter
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.89B	USD	1 Quarter
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$3.38B	USD	1 Quarter
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$3.38B	USD	1 Quarter
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$3.09B	USD	1 Quarter
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$3.09B	USD	1 Quarter
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$1.34B	USD	1 Quarter
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$1.34B	USD	1 Quarter
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$861.00M	USD	1 Quarter
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$861.00M	USD	1 Quarter
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.01B	USD	1 Quarter
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.01B	USD	1 Quarter
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$15.00M	USD	1 Quarter
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$15.00M	USD	1 Quarter
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$562.00M	USD	1 Quarter
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$562.00M	USD	1 Quarter
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$500.00M	USD	1 Quarter
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$500.00M	USD	1 Quarter
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$260.00M	USD	1 Quarter
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$260.00M	USD	1 Quarter
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	1 Quarter
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	1 Quarter
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$746.00M	USD	1 Quarter
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$746.00M	USD	1 Quarter
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	1 Quarter
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	1 Quarter
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$1.33B	USD	1 Quarter
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$1.33B	USD	1 Quarter
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$14.00M	USD	1 Quarter
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$14.00M	USD	1 Quarter
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-37.00M	USD	1 Quarter
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-37.00M	USD	1 Quarter
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.36B	USD	1 Quarter
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.36B	USD	1 Quarter
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.38B	USD	1 Quarter
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-1.38B	USD	1 Quarter
Payments on debt	`RepaymentsOfLongTermDebt`	$1.00M	USD	1 Quarter
Payments on debt	`RepaymentsOfLongTermDebt`	$1.00M	USD	1 Quarter
Payments on debt	`RepaymentsOfLongTermDebt`	$751.00M	USD	1 Quarter
Payments on debt	`RepaymentsOfLongTermDebt`	$751.00M	USD	1 Quarter
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$1.85B	USD	1 Quarter
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$1.85B	USD	1 Quarter
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$1.95B	USD	1 Quarter
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$1.95B	USD	1 Quarter
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$149.00M	USD	1 Quarter
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$149.00M	USD	1 Quarter
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$122.00M	USD	1 Quarter
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$122.00M	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$30.00M	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$30.00M	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$87.00M	USD	1 Quarter
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$87.00M	USD	1 Quarter
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-81.00M	USD	1 Quarter
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-81.00M	USD	1 Quarter
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-78.00M	USD	1 Quarter
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-78.00M	USD	1 Quarter
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.05B	USD	1 Quarter
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.05B	USD	1 Quarter
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.81B	USD	1 Quarter
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.81B	USD	1 Quarter
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$87.00M	USD	1 Quarter
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$87.00M	USD	1 Quarter
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-138.00M	USD	1 Quarter
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-138.00M	USD	1 Quarter
Net Decrease in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-2.99B	USD	1 Quarter
Net Decrease in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-2.99B	USD	1 Quarter
Net Decrease in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.24B	USD	1 Quarter
Net Decrease in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.24B	USD	1 Quarter
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.79B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.79B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.67B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.67B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.79B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.79B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.67B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $92 and $79 at March 31, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$5.67B	USD	Point-in-time

Comprehensive Income 24 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.82B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$2.82B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.76B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.76B	USD	1 Quarter
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-133.00M	USD	1 Quarter
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-133.00M	USD	1 Quarter
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$130.00M	USD	1 Quarter
Net unrealized gain (loss) on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$130.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$5.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$5.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$50.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$50.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$68.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$68.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-238.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-238.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-115.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-115.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-113.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-113.00M	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$2.71B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$2.71B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$4.65B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$4.65B	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.